Aurobindo Pharma Ltd (IN:AUROPHARMA)
:AUROPHARMA
Want to see IN:AUROPHARMA full AI Analyst Report?
Total Valuation
Aurobindo Pharma Ltd has a market cap or net worth of ₹869.95B. The enterprise value is ₹800.44B.
Market Cap₹869.95B
Enterprise Value₹800.44B
Share Statistics
Aurobindo Pharma Ltd has 580,801,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding580,801,640
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aurobindo Pharma Ltd’s return on equity (ROE) is 0.09 and return on invested capital (ROIC) is 7.33%.
Return on Equity (ROE)0.09
Return on Assets (ROA)0.06
Return on Invested Capital (ROIC)7.33%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee12.94M
Profits Per Employee1.35M
Employee Count26,015
Asset Turnover0.58
Inventory Turnover1.70
Valuation Ratios
The current PE Ratio of Aurobindo Pharma Ltd is 23.9. Aurobindo Pharma Ltd’s PEG ratio is 24.40.
PE Ratio23.9
PS Ratio2.25
PB Ratio2.00
Price to Fair Value2.00
Price to FCF26.80
Price to Operating Cash Flow29.07
PEG Ratio24.40
Income Statement
In the last 12 months, Aurobindo Pharma Ltd had revenue of 336.53B and earned 35.05B in profits. Earnings per share was 60.34.
Revenue336.53B
Gross Profit131.96B
Operating Income50.78B
Pretax Income51.12B
Net Income35.05B
EBITDA72.74B
Earnings Per Share (EPS)60.34
Cash Flow
In the last 12 months, operating cash flow was 28.85B and capital expenditures -13.63B, giving a free cash flow of 15.22B billion.
Operating Cash Flow28.85B
Free Cash Flow15.22B
Free Cash Flow per Share26.20
Dividends & Yields
Aurobindo Pharma Ltd pays an annual dividend of ₹4, resulting in a dividend yield of 0.33%
Dividend Per Share₹4
Dividend Yield0.33%
Payout Ratio6.79%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change36.71%
50-Day Moving Average1.44K
200-Day Moving Average1.24K
Relative Strength Index (RSI)59.88
Average Volume (3m)40.80K
Important Dates
Aurobindo Pharma Ltd upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateMay 21, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Aurobindo Pharma Ltd as a current ratio of 1.81, with Debt / Equity ratio of 21.31%
Current Ratio1.81
Quick Ratio1.15
Debt to Market Cap0.10
Net Debt to EBITDA-0.25
Interest Coverage Ratio13.22
Taxes
In the past 12 months, Aurobindo Pharma Ltd has paid 16.09B in taxes.
Income Tax16.09B
Effective Tax Rate0.31
Enterprise Valuation
Aurobindo Pharma Ltd EV to EBITDA ratio is 10.17, with an EV/FCF ratio of 26.16.
EV to Sales2.20
EV to EBITDA10.17
EV to Free Cash Flow26.16
EV to Operating Cash Flow13.42
Balance Sheet
Aurobindo Pharma Ltd has ₹88.92B in cash and marketable securities with ₹77.94B in debt, giving a net cash position of ₹10.98B billion.
Cash & Marketable Securities₹88.92B
Total Debt₹77.94B
Net Cash₹10.98B
Net Cash Per Share₹18.90
Tangible Book Value Per Share₹561.29
Margins
Gross margin is 44.07%, with operating margin of 15.09%, and net profit margin of 10.41%.
Gross Margin44.07%
Operating Margin15.09%
Pretax Margin15.19%
Net Profit Margin10.41%
EBITDA Margin21.61%
EBIT Margin16.33%
Analyst Forecast
The average price target for Aurobindo Pharma Ltd is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast6.08%
EPS Growth Forecast0.77%